NCT01316055View on ClinicalTrials.gov

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

September 30, 2011

Conditions
Renal Insufficiency
Interventions
DRUG

Dalfampridine-ER

2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up

Trial Locations (2)

33143

MRA Clinical Research, South Miami

92801

ACRI - Phase 1, Anaheim

Sponsors
All Listed Sponsors
lead

Acorda Therapeutics

INDUSTRY